Literature DB >> 22200790

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).

Sameh Hafsi1, Franca Maria Pezzino, Saverio Candido, Giovanni Ligresti, Demetrios A Spandidos, Zohra Soua, James A McCubrey, Salvatore Travali, Massimo Libra.   

Abstract

The most common therapeutic approach for many cancers is chemotherapy. However, many patients relapse after treatment due to the development of chemoresistance. Recently, targeted therapies represent novel approaches to destroy cancer cells. The PI3K/PTEN/AKT pathway is a key signaling pathway involved in the regulation of cell growth. Dysregulated signaling of this pathway may be associated with activating mutations of PI3K-related genes. Analyses of these mutations reveal that they increase the PI3K signal, stimulate downstream Akt signaling, promote growth factor-independent growth and increase cell invasion and metastasis. In this review, we summarize the PI3K/PTEN/AKT pathway genetic alterations in cancer and their potential clinical applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200790     DOI: 10.3892/ijo.2011.1312

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  67 in total

1.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors:  Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  XRCC1 Gene Polymorphisms and miR-21 Expression in Patients with Colorectal Carcinoma.

Authors:  Hanan Fouad; Dina Sabry; Heba Morsi; Hany Shehab; Naglaa F Abuzaid
Journal:  Eurasian J Med       Date:  2017-06

3.  Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.

Authors:  Huanjie Shao; Kai Jing; Esraa Mahmoud; Haihong Huang; Xianjun Fang; Chunrong Yu
Journal:  Mol Cancer Ther       Date:  2013-10-14       Impact factor: 6.261

4.  Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

Authors:  Kenneth K W To; Brian Tomlinson
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  MicroRNA-21 promotes phosphatase gene and protein kinase B/phosphatidylinositol 3-kinase expression in colorectal cancer.

Authors:  Wei-Zhong Sheng; Yu-Sheng Chen; Chuan-Tao Tu; Juan He; Bo Zhang; Wei-Dong Gao
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

6.  Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

Authors:  Asunción Díaz-Serrano; Barbara Angulo; Carolina Dominguez; Roberto Pazo-Cid; Antonieta Salud; Paula Jiménez-Fonseca; Ana Leon; Maria Carmen Galan; Maria Alsina; Fernando Rivera; J Carlos Plaza; Luis Paz-Ares; Fernando Lopez-Rios; Carlos Gómez-Martín
Journal:  Oncologist       Date:  2018-04-26

Review 7.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

8.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 9.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

10.  Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN.

Authors:  Niubys Cayado-Gutiérrez; Vera L Moncalero; Eliana M Rosales; Walter Berón; Edgardo E Salvatierra; Daiana Alvarez-Olmedo; Martín Radrizzani; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2012-08-21       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.